newsfilter
← Interviews
All-In Podcast1h 5m

Dave Ricks, CEO of Eli Lilly | The All-In Interview

Dave Ricks, Friedberg

Interview, Fireside Chat

Under CEO Dave Ricks, Eli Lilly has expanded its market capitalization to $878 billion while dominating the GLP-1 weight loss market through innovations like tirzepatide and the upcoming oral drug orforglipron. These scientific breakthroughs address a global obesity crisis affecting billions, with the company investing heavily in domestic manufacturing and AI-driven research to sustain high-growth revenue projections. Despite facing political scrutiny over pricing and reimbursement limitations, Lilly is leveraging a rapid development culture and direct-to-consumer platforms to maintain industry leadership and expand treatment access.